Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating

SNDX +1.11%

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)  is one of the most promising stocks with huge upside potential. On November 24, Barclays raised the firm’s price target on Syndax to $35 from $22, while maintaining an Overweight rating on the shares. The firm’s sentiment followed an overall update on the company’s model after speaking with management.

Earlier the same month, Syndax Pharmaceuticals also released its Q3 2025 earnings report, where the company disclosed that it achieved total revenue of $45.9 million, which was a 21% sequential growth propelled by two key medicines: Revvvi Forge and Nick Timbo, both characterized as first and best-in-class therapies. The company’s commercial strategy is showing success with strong patient uptake and sustained growth potential for both products.

Nick Timbo alone saw a net revenue increase of 27% over the prior quarter and is annualizing at ~$200 million. Revvvi Forge is rapidly expanding its addressable market following its FDA approval for relapse-refractory NPM1-mutated AML, in addition to its initial KMT2A-rearranged acute leukemia indication. Its position in the treatment landscape was further solidified by its addition to the NCCN guidelines.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer.

While we acknowledge the potential of SNDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.